Statins and autoimmune diseases

Abstract

Besides the well-known lipid-lowering effect, statins display nonlipid-lowering pharmacological activities. In vitro and in vivo studies suggest that statins have direct anti-inflammatory, anti-thrombotic and plaque-stabilizing effects via a number of mechanisms. A direct immunomodulatory effect has been also demonstrated in in vitro and in vivo experimental models. In addition to traditional risk factors, systemic inflammation, immune-mediated responses and thrombophilia have been suggested to play a major role in sustaining the premature atherosclerosis in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. This review focuses on the anti-inflammatory and immunomodulating mechanisms of statins as demonstrated in in vitro and in vivo experimental models, providing new insights for the use of statins in treating systemic autoimmune diseases both for their anti-atherosclerotic activity and for their pleiotropic effects on inflammation, haemostasis and the immune responses.

Keywords

statins atherosclerosis inflammation immunomodulation autoimmune diseases

Get full access to this article

View all access options for this article.

References

Vaughan CJ , Gotto AM. Update on statins: 2003 . Circulation 2004; 110: 886-892 .

Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability . Cardiovas Res 2000; 47: 648-657 .

Weitz-Schmidt G , Welzenbach K , Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site . Nature Medicine 2001; 7: 687-692 .

Sparrow CP , Burton C , Hernandez M et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering . Arterioscler Thromb Vasc Biol 2001; 21: 115-121 .

Diomede L , Albani D , Sottocorno M et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products . Arterioscler Thromb Vasc Biol 2001; 21: 1256-1258 .

Meroni PL , Tremoli E. Modulation of adhesion molecule expression on endothelial cells: to be or not to be ? J Thromb Haemost 2003; 1: 2280-2282 .

Kwak B , Mulhaupt F , Myit S , Mach F. Statins as a newly recognized type of immunomodulator . Nature Medicine 2000; 6: 1399-1402 .

Sadeghi MM , Tiglio A , Sadigh K et al. Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors . Transplantation 2001; 71: 1262-1268 .

Neuhaus O , Strasser-Fuchs S , Fazekas F et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS . Neurology 2002; 59: 970-971 .

10.

Ridker PM , Rifai N , Clearfield M et al. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators: measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events . N Engl J Med 2001; 344: 1959-1965 .

11.

Wibaut-Berlaimont V , Randi AM , Mandryko V , Lunnon MW , Haskard DO , Naoumova RP. Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis . J Thromb Haemost 2005; 3: 677-685 .

12.

Youssef S , Stuve O , Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease . Nature 2002; 420: 78-84 .

13.

Aktas O , Waiczies S , Smorodchenko A et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin . J Exp Med 2003; 197: 725-733 .

14.

Nath N , Giri S , Prasad R , Singh A , Singh I. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy . J Immunol 2004; 172: 1273-1286 .

15.

Greenwood J , Walters CE , Pryce G et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis . Faseb J 2003; 17: 905-907 .

16.

Leung BP , Sattar N , Crilly A et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis . J Immunol 2003; 170: 1524-1530 .

17.

Lawman S , Mauri C , Jury EC , Cook HT , Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand Black/White F1 mice . J Immunol 2004; 173: 7641-7646 .

18.

Fischetti F , Carretta R , Borotto G et al. Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation . Clin Exp Immunol 2004; 135: 186-193 .

19.

McCarey DW , McInnes IB , Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial . Lancet 2004; 363: 2015-2021 .

20.

Abud-Mendoza C , de la Fuente H , Cuevas-Orta E et al. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study . Lupus 2003; 12: 607-611 .

21.

Noel B. Risks and benefits of statins in lupus erythematosus . Arch Int Med 2004; 164: 107-108 .

22.

Meroni PL , Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome . Curr Opin Rheumatol 2001; 13: 377-382 .

23.

Meroni PL , Raschi E , Testoni C et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype . Arthritis Rheum 2001; 44: 2870-2878 .

24.

Ferrara DE , Liu X , Espinola RG et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model . Arthritis Rheum 2003; 48: 3272-3279 .

25.

Katznelson S , Wang XM , Chia D et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro . J Heart Lung Transpl 1998; 17: 335-340 .

26.

Lusis AJ. Atherosclerosis . Nature 2000; 407: 233-241 .

27.

Van Doornum S , McColl G , Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis . Ann Rheum Dis 2004; 63: 1571-1575 .

28.

Riboldi P , Gerosa M , Luzzana C , Catelli L. Cardiac involvement in systemic autoimmune diseases . Clin Rev Allergy Immunol 2002; 23: 247-261 .

29.

Aprahamian T , Rifkin I , Bonegio R et al. Impaired clearance of apoptotic cells promotes synergy between atherogeneis and auto-immune disease . J Exp Med 2004; 199: 1121-1131 .

30.

Kelley VE , Izui S. Enriched lipid diet accelerates lupus nephritis in NZB × W mice: synergistic action of immune complexes and lipid in glomerular injury . Am J Pathol 1983; 111: 288-297 .

31.

Ehrenstein M , Jury EC , Mauri C. Statins for atherosclerosis-as good as it gets ? N Engl J Med 2005; 352: 73-75 .

32.

Hillyard DZ , Cameron AJM , McDonald KJ et al. Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease . Atherosclerosis 2004; 175: 305-313 .

33.

Poloso NJ , Roche PA. Association of MHC class II-peptide complexes with plasma membrane microdomains . Curr Opin Immunol 2004; 16: 103-107 .

34.

Ghittoni R , Patrussi L , Pirozzi K et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases . FASEB J published on line 27 January 2005.

35.

Vasa M , Fichtlscherer S , Adler K et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease . Circulation 2001; 103: 2885-2890 .

36.

Kureishi Y , Luo Z , Shiojima I et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals . Nature Medicine 2000; 6: 1004-1010 .

37.

Bacon PA , Raza K , Banks MJ et al. The role of endothelial cell dysfunction in the cardiovascular mortality of RA . Int Rev Immunol 2002; 21: 1-17 .

38.

Grisar J , Aletaha D , Steiner CW et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis . Circulation 2005; 111: 204-211 .